Maria Cardenas, MD
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1154408375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 327 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 36 manufacturers reported payments, led by Novo Nordisk at 25.4% of the total. Reporting peaked in 2021 at $1,997 and has fallen 64.6% since, to $707 in 2025.
Across 327 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$1K
- Amgen$1K
- Xeris Pharmaceuticals, Inc.$665
- Tandem Diabetes Care, Inc.$628
- Insulet Corporation$414
- plus $3K from 30 others
What the payments were for
- Food & beverage$9,26099%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 110 | $2,377 |
| Abbott | 36 | $1,309 |
| Amgen(2 entities) | 32 | $1,190 |
| Xeris Pharmaceuticals, Inc. | 13 | $665 |
| Tandem Diabetes Care, Inc. | 9 | $628 |
| Insulet Corporation | 5 | $414 |
| Lilly USA, LLC | 21 | $379 |
| Mannkind Corporation | 11 | $270 |
| Dexcom, Inc. | 12 | $269 |
| Johnson & Johnson(2 entities) | 12 | $249 |
| Radius Health, Inc. | 6 | $246 |
| Medtronic | 2 | $236 |
| Boehringer Ingelheim | 8 | $174 |
| AbbVie | 8 | $153 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $115 |
| Corcept Therapeutics | 3 | $92 |
| Sanofi-aventis U.S. LLC | 4 | $71 |
| AstraZeneca | 4 | $66 |
| Merck | 5 | $61 |
| GSK | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Ascendis Pharma Endocrinology Inc | 2 | $29 |
| Bioventus LLC | 1 | $27 |
| Braintree Laboratories, Inc. | 2 | $25 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Sobi, Inc | 1 | $21 |
| Covidien LP | 1 | $20 |
| GRT US Holding, Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| UCB, Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GVOKE HYPOPEN$526
- FREESTYLE LIBRE 3$473
- TEPEZZA$473
- Ozempic$350
- t:slim X2 Insulin Pump with Control-IQ$251
- Wegovy$239
- Omnipod$233
- FreeStyle Libre Pro$226
- FreeStyle Libre$164
- RYBELSUS$116
- t-slim insulin pump$116
- EVENITY$112
- Tymlos$111
- Saxenda$100
How this compares
$9,349 in reported general payments places this provider in the 80th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 75 | $81,037 |
| OzempicSemaglutide | 40 | $39,301 |
| RybelsusSemaglutide | 18 | $33,063 |
| TymlosAbaloparatide | 12 | $31,327 |
| TrulicityDulaglutide | 22 | $26,544 |
| FarxigaDapagliflozin Propanediol | 20 | $16,974 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $12,790 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 11 | $11,931 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $9,400 |
| Gvoke Hypopen 2-PackGlucagon | 15 | $9,198 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 49 | $6,575 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 12 | $5,927 |
| Cinacalcet Hcl | 20 | $1,356 |
| Levothyroxine Sodium | 76 | $947 |
| Methimazole | 55 | $616 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $174 | $81,03775 claims |
| Novo NordiskOzempic, Rybelsus | $2,377 | $72,36358 claims |
| Radius Health, Inc.Tymlos | $246 | $31,32712 claims |
| Lilly USA, LLCTrulicity | $379 | $26,54422 claims |
| AstraZenecaFarxiga | $66 | $16,97420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.